Suppr超能文献

炎症小体与白细胞介素-1生物学在同种异体移植功能障碍发病机制中的作用

Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.

作者信息

Weigt S Samuel, Palchevskiy Vyacheslav, Belperio John A

出版信息

J Clin Invest. 2017 Jun 1;127(6):2022-2029. doi: 10.1172/JCI93537.

Abstract

Inflammasomes are high-molecular-weight cytosolic complexes that mediate the activation of caspases. There are many inflammasomes, and each is influenced by a unique pattern-recognition receptor response. Two signals are typically involved in the inflammasome pathways. Signal one involves recognition of pathogen-associated molecular patterns (PAMPs), such as LPS or other colonizing/invading microbes, that interact with TLRs, which induce the downstream production of pro-IL-1β. This is followed by signal two, which involves recognition of PAMPs or damage-associated molecular patterns (DAMPs), such as uric acid or ATP, via NLRP3, which leads to caspase-1-dependent cleavage of pro-IL-1β to active IL-1β and pyroptosis. Ultimately, these two signals cause the release of multiple proinflammatory cytokines. Both PAMPs and DAMPs can be liberated by early insults to the allograft, including ischemia/reperfusion injury, infections, and rejection. The consequence of inflammasome activation and IL-1 expression is the upregulation of adhesion molecules and chemokines, which leads to allograft neutrophil sequestration, mononuclear phagocyte recruitment, and T cell activation, all of which are key steps in the continuum from allograft insult to chronic allograft dysfunction.

摘要

炎性小体是介导半胱天冬酶激活的高分子量胞质复合物。炎性小体有多种,每种都受独特的模式识别受体反应影响。炎性小体途径通常涉及两个信号。信号一涉及对病原体相关分子模式(PAMP)的识别,如脂多糖或其他定植/侵入性微生物,它们与Toll样受体(TLR)相互作用,诱导前白细胞介素-1β的下游产生。随后是信号二,它涉及通过NLRP3识别PAMP或损伤相关分子模式(DAMP),如尿酸或三磷酸腺苷,这导致前白细胞介素-1β被半胱天冬酶-1依赖性切割为活性白细胞介素-1β并引发细胞焦亡。最终,这两个信号导致多种促炎细胞因子的释放。PAMP和DAMP都可由同种异体移植物早期损伤释放,包括缺血/再灌注损伤、感染和排斥反应。炎性小体激活和白细胞介素-1表达的结果是黏附分子和趋化因子上调,导致同种异体移植物中性粒细胞滞留、单核吞噬细胞募集和T细胞激活,所有这些都是从同种异体移植物损伤到慢性同种异体移植物功能障碍连续过程中的关键步骤。

相似文献

4
Role of Inflammasome in Chronic Kidney Disease.炎症小体在慢性肾脏病中的作用。
Adv Exp Med Biol. 2019;1165:407-421. doi: 10.1007/978-981-13-8871-2_19.
5
Inflammasome as a promising therapeutic target for cancer.炎症小体作为癌症治疗的一个有前景的靶点。
Life Sci. 2019 Aug 15;231:116593. doi: 10.1016/j.lfs.2019.116593. Epub 2019 Jun 19.
7
Alarmins, inflammasomes and immunity.警报素、炎性小体与免疫。
Biomed J. 2012 Nov-Dec;35(6):437-49. doi: 10.4103/2319-4170.104408.
8
[The inflammasomes: platforms of innate immunity].[炎症小体:固有免疫的平台]
Med Sci (Paris). 2013 Nov;29(11):975-84. doi: 10.1051/medsci/20132911013. Epub 2013 Nov 20.
10
Inflammasome and autophagy regulation - a two-way street.炎症小体与自噬调控:双向作用。
Mol Med. 2017 Sep;23:188-195. doi: 10.2119/molmed.2017.00077. Epub 2017 Jul 24.

引用本文的文献

本文引用的文献

3
Inflammasomes: mechanism of assembly, regulation and signalling.炎症小体:组装、调控和信号转导机制。
Nat Rev Immunol. 2016 Jul;16(7):407-20. doi: 10.1038/nri.2016.58. Epub 2016 Jun 13.
7
Inflammasome effects in GvHD.移植物抗宿主病中的炎性小体效应
Oncotarget. 2015 Nov 17;6(36):38444-5. doi: 10.18632/oncotarget.6307.
10
Formation of the inflammasome during cardiac allograft rejection.心脏同种异体移植排斥反应期间炎性小体的形成。
Int J Cardiol. 2015 Dec 15;201:328-30. doi: 10.1016/j.ijcard.2015.08.070. Epub 2015 Aug 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验